CN116159102A - Traditional Chinese medicine composition for treating postprandial discomfort syndrome as well as preparation method and application thereof - Google Patents
Traditional Chinese medicine composition for treating postprandial discomfort syndrome as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN116159102A CN116159102A CN202310156735.2A CN202310156735A CN116159102A CN 116159102 A CN116159102 A CN 116159102A CN 202310156735 A CN202310156735 A CN 202310156735A CN 116159102 A CN116159102 A CN 116159102A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- preparation
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 87
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- 230000000291 postprandial effect Effects 0.000 title claims abstract description 20
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 19
- 239000000843 powder Substances 0.000 claims abstract description 15
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 12
- 235000017309 Hypericum perforatum Nutrition 0.000 claims abstract description 12
- 244000141009 Hypericum perforatum Species 0.000 claims abstract description 12
- 241001522129 Pinellia Species 0.000 claims abstract description 12
- 235000008632 Santalum album Nutrition 0.000 claims abstract description 12
- 240000000513 Santalum album Species 0.000 claims abstract description 12
- 235000008326 Trichosanthes anguina Nutrition 0.000 claims abstract description 12
- 244000078912 Trichosanthes cucumerina Species 0.000 claims abstract description 12
- 244000273928 Zingiber officinale Species 0.000 claims abstract description 12
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 12
- 201000006549 dyspepsia Diseases 0.000 claims abstract description 12
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 12
- 235000008397 ginger Nutrition 0.000 claims abstract description 12
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 11
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 11
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 11
- 241001673966 Magnolia officinalis Species 0.000 claims abstract description 11
- 241000222336 Ganoderma Species 0.000 claims abstract description 10
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 10
- 230000036506 anxiety Effects 0.000 claims abstract description 9
- 235000018958 Gardenia augusta Nutrition 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims description 31
- 239000000243 solution Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 12
- 210000002966 serum Anatomy 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 10
- 241001106477 Paeoniaceae Species 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 239000003629 gastrointestinal hormone Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000006072 paste Substances 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 208000020401 Depressive disease Diseases 0.000 claims description 4
- 238000009098 adjuvant therapy Methods 0.000 claims description 4
- 206010025482 malaise Diseases 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 abstract description 27
- 230000000694 effects Effects 0.000 abstract description 16
- 210000004185 liver Anatomy 0.000 abstract description 16
- 206010003591 Ataxia Diseases 0.000 abstract description 6
- 206010010947 Coordination abnormal Diseases 0.000 abstract description 6
- 208000016290 incoordination Diseases 0.000 abstract description 6
- 230000001105 regulatory effect Effects 0.000 abstract description 6
- 206010027940 Mood altered Diseases 0.000 abstract description 5
- 206010000060 Abdominal distension Diseases 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 24
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 16
- 210000000813 small intestine Anatomy 0.000 description 14
- 208000035736 spondylodysplastic type Ehlers-Danlos syndrome Diseases 0.000 description 14
- 230000002496 gastric effect Effects 0.000 description 10
- 230000030136 gastric emptying Effects 0.000 description 9
- 102400000921 Gastrin Human genes 0.000 description 8
- 108010052343 Gastrins Proteins 0.000 description 8
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 7
- 235000019525 fullness Nutrition 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- YPELFRMCRYSPKZ-UHFFFAOYSA-N 4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide Chemical compound CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1OCCN(CC=2C=CC(F)=CC=2)C1 YPELFRMCRYSPKZ-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 229960004085 mosapride Drugs 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 description 3
- 206010038743 Restlessness Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 239000002249 anxiolytic agent Substances 0.000 description 3
- 210000000702 aorta abdominal Anatomy 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000008451 emotion Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 210000001187 pylorus Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 240000008397 Ganoderma lucidum Species 0.000 description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 2
- 101800001586 Ghrelin Proteins 0.000 description 2
- 102400000442 Ghrelin-28 Human genes 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000005176 gastrointestinal motility Effects 0.000 description 2
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000202726 Bupleurum Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241001481833 Coryphaena hippurus Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 206010059186 Early satiety Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- QQQIECGTIMUVDS-UHFFFAOYSA-N N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4-dimethoxybenzamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NCC1=CC=C(OCCN(C)C)C=C1 QQQIECGTIMUVDS-UHFFFAOYSA-N 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229960005302 itopride Drugs 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating postprandial discomfort syndrome, a preparation method and application thereof. A traditional Chinese medicine composition comprises the following raw materials in parts by weight: 3-20 parts of radix bupleuri, 3-20 parts of radix scutellariae, 3-18 parts of ginger processed pinellia, 3-30 parts of lucid ganoderma, 3-30 parts of cassia twig, 3-30 parts of raw white paeony root, 3-15 parts of magnolia officinalis, 2-15 parts of sandalwood, 0.1-3 parts of pearl powder, 1-10 parts of hypericum perforatum, 3-18 parts of cape jasmine and 3-24 parts of snakegourd fruit; the traditional Chinese medicine composition has the effects of soothing liver, harmonizing stomach, regulating qi and relieving distention, and is suitable for patients with functional dyspepsia and postprandial discomfort syndromes with incoordination between liver and stomach, particularly patients with bad moods such as anxiety and depression.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating postprandial discomfort syndrome, a preparation method and application thereof.
Background
Functional dyspepsia (Functional dyspepsia, FD) refers to a disease that has one or more symptoms of postprandial satiety, early satiety, upper abdominal pain, and upper abdominal burning, and cannot be explained by organic, systemic, metabolic diseases, etc. that cause the symptoms. FD is divided into 2 subtypes, namely, upper abdominal pain syndrome (Epigastric pain syndrome, EPS) and postprandial discomfort syndrome (Postprandial distress syndrome, PDS) according to the main symptom characteristics, symptom patterns, and pathophysiological mechanisms associated with symptoms of patients. The prevalence of PDS is up to 60% in FD population, and because the disease is difficult to radically cure and easy to repeatedly attack, the life quality of patients is obviously affected, and most PDS patients are accompanied with different degrees of bad moods such as anxiety and depression.
At present, the clinic uses gastrointestinal motility promoting, acid suppressing and anxiolytic drugs as main drugs, and also has beneficial bacteria, digestive enzymes or anti-infective drugs. Gastric dyskinesia is an important pathogenesis of PDS, and thus, gastric motility-promoting drugs are used as a first-line drug for PDS. The most commonly used clinical prokinetic drugs such as mosapride, itopride, domperidone and the like, but researches show that the drugs have certain limitations in curative effect and safety. The prokinetic drugs have good curative effects in reducing the overall symptoms of the diseases, but have lower curative effects in improving the life quality of patients, and in addition, certain drugs have side effects of arrhythmia or extrapyramidal reactions, so that the clinical application of the prokinetic drugs is questionable. In summary, the pathogenesis of postprandial malaise is a complex network, and the occurrence of this disease may be caused by the co-participation of multiple factors. The existing chemotherapy drugs are mainly aimed at the unilateral pathogenesis of the disease, and the long-term curative effect is unstable, so that the existing drugs are easy to have the conditions of unsatisfactory curative effect, easy recurrence after stopping the drug, and lack of therapeutic intervention for improving the bad emotion such as anxiety and depression. The types of medicines aiming at postprandial discomfort syndromes in the market at present are limited, and the types of Chinese patent medicines are single. In terms of curative effect, besides improving gastrointestinal motility and promoting gastrointestinal peristalsis, few Chinese patent medicines capable of taking the emotion of a patient into consideration are available.
Disclosure of Invention
Therefore, the technical problems to be solved by the invention are that the traditional medicine has unsatisfactory curative effect, easy recurrence after stopping the medicine, more adverse reactions, difficult improvement of bad moods such as anxiety depression and the like, so as to provide a traditional Chinese medicine composition for treating postprandial discomfort syndrome, a preparation method and application thereof.
For this purpose, the invention provides the following technical scheme:
a traditional Chinese medicine composition comprises the following raw materials in parts by weight: 3-20 parts of radix bupleuri, 3-20 parts of radix scutellariae, 3-18 parts of ginger processed pinellia, 3-30 parts of lucid ganoderma, 3-30 parts of cassia twig, 3-30 parts of raw white paeony root, 3-15 parts of magnolia officinalis, 2-15 parts of sandalwood, 0.1-3 parts of pearl powder, 1-10 parts of hypericum perforatum, 3-18 parts of cape jasmine and 3-24 parts of snakegourd fruit.
Optionally, the raw materials comprise the following components in parts by weight:
3-18 parts of radix bupleuri, 3-15 parts of radix scutellariae, 3-15 parts of ginger processed pinellia, 3-20 parts of lucid ganoderma, 3-20 parts of cassia twig, 3-20 parts of raw white paeony root, 3-12 parts of magnolia officinalis, 2-10 parts of sandalwood, 0.1-1.5 parts of pearl powder, 1-9 parts of hypericum perforatum, 3-15 parts of gardenia and 3-18 parts of snakegourd fruit.
Optionally, the raw materials comprise the following components in parts by weight:
5-15 parts of radix bupleuri, 3-12 parts of radix scutellariae, 3-12 parts of ginger processed pinellia, 3-12 parts of lucid ganoderma, 3-12 parts of cassia twig, 3-15 parts of raw white paeony root, 3-10 parts of magnolia officinalis, 2-8 parts of sandalwood, 0.1-1 part of pearl powder, 1-6 parts of hypericum perforatum, 3-12 parts of gardenia and 3-12 parts of snakegourd fruit.
Optionally, the raw materials comprise the following components in parts by weight:
5-10 parts of radix bupleuri, 3-9 parts of radix scutellariae, 3-9 parts of ginger processed pinellia, 3-9 parts of lucid ganoderma, 3-9 parts of cassia twig, 9-15 parts of raw white paeony root, 6-10 parts of magnolia officinalis, 2-5 parts of sandalwood, 0.3-1 part of pearl powder, 1-3 parts of hypericum perforatum, 3-9 parts of cape jasmine and 3-9 parts of snakegourd fruit.
A method of preparing the traditional Chinese medicine composition, comprising:
the preparation method comprises the steps of weighing raw materials according to a formula, and extracting with water.
Optionally, the method comprises the following steps:
weighing the raw materials according to the formula, adding 1-2 times of water, soaking for 0.4-0.5 hr, decocting the medicinal liquid to 100deg.C, cooling to 60-80deg.C, decocting for 0.4-0.5 hr, and filtering to obtain first extractive solution and residue;
adding water 1-2 times of the weight of the medicinal residues into the medicinal residues, decocting the medicinal liquid to 100deg.C, cooling to 60-80deg.C, decocting for 0.4-0.5 hr, and filtering to obtain second extractive solution;
mixing the first extractive solution and the second extractive solution.
A Chinese medicinal preparation comprises the Chinese medicinal composition or the Chinese medicinal composition prepared by the preparation method as active ingredient.
Optionally, the composition also comprises pharmaceutically acceptable auxiliary materials;
optionally, the form of the traditional Chinese medicine preparation comprises a liquid preparation or a solid preparation;
optionally, the dosage form of the traditional Chinese medicine preparation comprises injection, tablet, capsule, powder, granule or paste.
The traditional Chinese medicine composition, the traditional Chinese medicine composition prepared by the preparation method of the traditional Chinese medicine composition or the traditional Chinese medicine preparation has the following purposes:
(1) Use in the manufacture of a medicament for the alleviation, adjuvant treatment or treatment of functional dyspepsia;
(2) The application of the composition in preparing medicines for relieving, assisting in treating or treating anxiety and depression;
(3) The use in the manufacture of a medicament for the relief, adjuvant treatment or treatment of functional dyspepsia with anxiety depression;
(4) Use in the manufacture of a medicament for improving the protein expression levels of gastrointestinal hormones and ghrelins in serum;
optionally, the functional dyspepsia is postprandial malaise syndrome.
The inventor of the invention is engaged in the clinical and basic research of treating functional gastroenteropathy by traditional Chinese medicine for a long time, and the inventor of the invention is in keeping with the key pathogenesis of PDS, and combines clinical experience to create a pharmaceutical composition aiming at PDS with incoordination between liver and stomach. According to preliminary statistics, the pharmaceutical composition provided by the invention can effectively relieve adverse moods such as anxiety and depression of patients and reduce the use rate of the anti-anxiety and depression drugs of the patients besides effectively improving postprandial discomfort and related symptoms of the patients in the use of PDS outpatients. Further, the invention also finds in basic experiments: compared with a PDS rat with incoordination between liver and stomach, the pharmaceutical composition provided by the invention can effectively improve the gastric emptying rate and the small intestine propulsion rate of a model rat, effectively lighten the anxiety and emotion states of the rat, improve the protein expression levels of gastrointestinal hormones such as MTL, GAS, 5-HT, LP and the like and brain intestinal peptide in serum, and has better curative effect than the positive drug mosapride in certain aspects.
The method comprises the following steps: radix bupleuri: disperse and dispel heat, soothe liver and relieve depression, and lift yang qi.
Radix Scutellariae Baicalensis: clear heat and dry dampness, purge fire and detoxify.
Ginger processed pinellia tuber: warm middle energizer and resolve phlegm, reduce adverse flow of qi and arrest vomiting. Can be used for treating emesis due to phlegm and fluid retention, and gastric fullness.
Ganoderma lucidum: tonify qi and tranquilize, relieve cough and asthma. Can be used for treating restlessness and anorexia.
Ramulus Cinnamomi: induce sweat to relieve muscle, warm and unblock meridians, strengthen yang and transform qi, calm pulse and reduce qi. Can be used for treating abdominal crymodynia and running dolphin.
Raw white peony root: nourishing blood, regulating menstruation, astringing yin, suppressing sweating, softening liver, relieving pain, and suppressing liver yang.
Cortex Magnoliae officinalis: dry dampness and remove phlegm, and lower qi and remove fullness. Is used for treating damp stagnation, gastric fullness, vomiting and diarrhea, food stagnation and qi stagnation.
Sandalwood: promoting qi circulation, warming spleen and stomach, stimulating appetite and relieving pain. Can be used for treating stagnation of qi due to cold accumulation, and chest and diaphragm discomfort.
Pearl powder: tranquillizing, arresting convulsion, improving eyesight, eliminating nebula, detoxifying, promoting tissue regeneration, moisturizing skin and removing freckle. Can be used for treating palpitation and insomnia.
Hypericum perforatum L.): liver soothing, qi stagnation relieving, heat clearing, dampness removing, repercussive and lactation promoting. Can be used for treating stagnation of liver-qi and emotional disorder.
Gardenia jasminoides ellis: purging pathogenic fire, relieving restlessness, clearing heat, promoting diuresis, cooling blood and removing toxic substances.
All snakegourd fruit: clear heat and remove phlegm, relieve chest stuffiness and dissipate nodulation, moisten dryness and smooth intestines. Can be used for treating chest stuffiness and fullness.
The technical scheme of the invention has the following advantages:
1. the traditional Chinese medicine composition is characterized by comprising the following raw materials in parts by weight: 3-20 parts of radix bupleuri, 3-20 parts of radix scutellariae, 3-18 parts of ginger processed pinellia, 3-30 parts of lucid ganoderma, 3-30 parts of cassia twig, 3-30 parts of raw white paeony root, 3-15 parts of magnolia officinalis, 2-15 parts of sandalwood, 0.1-3 parts of pearl powder, 1-10 parts of hypericum perforatum, 3-18 parts of cape jasmine and 3-24 parts of snakegourd fruit; the traditional Chinese medicine composition has the effects of soothing liver, harmonizing stomach, regulating qi and relieving distention, and is suitable for patients with functional dyspepsia and postprandial discomfort syndromes with incoordination between liver and stomach, particularly patients with bad moods such as anxiety and depression. Wherein, the north bupleurum root is bitter and flat, enters liver and gall meridian, and dredges qi stagnation, which is a monarch drug. The scutellaria baicalensis is bitter and cold, clears liver and stomach evil heat, the ginger processed pinellia tuber is pungent and warm in nature, eliminates phlegm and reduces adverse qi, the whole snakegourd fruit is sweet and cold in nature, removes dirt, eliminates stagnation and stimulates the appetite, and the above medicinal herbs are used together, clear heat and reduce adverse qi, and assist stomach and reduce adverse qi, so that the medicine is a ministerial medicine. With the auxiliary functions of activating qi-flowing and relieving depression of cassia twig, radix paeoniae alba, magnolia officinalis, sandalwood and hypericum perforatum, the liver-soothing and qi-regulating effects of the monarch drug are enhanced. Gardenia is bitter and cold and good at relieving heat depression; the ganoderma lucidum has the effects of nourishing the heart and soothing the nerves, the pearl powder has the effects of soothing the liver and harmonizing the stomach, regulating qi and relieving distension, and the whole formula is used for treating the postprandial discomfort syndrome of the functional dyspepsia with incoordination between the liver and the stomach; therefore, the traditional Chinese medicine composition has the main functions of: has effects of soothing liver, regulating stomach function, regulating qi-flowing, and relieving flatulence, and can be used for treating syndrome of liver-stomach disharmony due to functional dyspepsia and postprandial discomfort. The evidence is that: distention and fullness in the stomach, belch, fullness in the stomach, emotional state, chest distress, happiness, restlessness, poor sleep, unsmooth stool, frequent urination, and tongue pulse: a pale red tongue with thin and white coating and a wiry pulse.
Furthermore, the preliminary statistics of the invention show that the traditional Chinese medicine composition can effectively improve the postprandial discomfort of patients, effectively relieve the bad moods of patients such as anxiety and depression and reduce the use rate of anxiolytic drugs of the patients in the use of PDS outpatients.
Furthermore, in basic research, compared with a PDS rat with liver-stomach disharmony syndrome accompanied with anxiety depression, the traditional Chinese medicine composition provided by the invention can effectively improve the gastric emptying rate and the small intestine propulsion rate of a model rat, so that the postprandial discomfort syndrome can be effectively improved, and simultaneously, the protein expression levels of gastrointestinal hormones such as GAS, 5-HT and the like and the ghrelin in serum are improved, so that the anxiety state of the rat is effectively relieved, and the curative effect of the traditional Chinese medicine composition is superior to that of a positive medicine mosapride in some aspects.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings that are needed in the description of the embodiments or the prior art will be briefly described, and it is obvious that the drawings in the description below are some embodiments of the present invention, and other drawings can be obtained according to the drawings without inventive effort for a person skilled in the art.
FIG. 1 shows the results of measurement of gastric emptying rate of each group in the experimental example of the present invention; the ordinate unit is;
FIG. 2 shows the results of the small intestine propulsion rate test for each group in the experimental example of the present invention; the ordinate unit is;
FIG. 3 is a graph showing the intestinal thrust rate of each group in the experimental example of the present invention; a, B, C, D, E, F, G, H, I, J, K in the figure corresponds to a blank group, a model group, an example 1 group, an example 2 group, an example 3 group, an example 4 group, an example 5 group, an example 6 group, an example 7 group, an example 8 group and a positive drug group in sequence;
FIG. 4 shows the GAS test results for each group in the experimental example of the present invention; the ordinate unit is pg/ml;
FIG. 5 shows the results of the 5-HT assay for each of the groups in the experimental examples of the present invention; the ordinate is in pg/ml.
Detailed Description
The following examples are provided for a better understanding of the present invention and are not limited to the preferred embodiments described herein, but are not intended to limit the scope of the invention, any product which is the same or similar to the present invention, whether in light of the present teachings or in combination with other prior art features, falls within the scope of the present invention.
The specific experimental procedures or conditions are not noted in the examples and may be followed by the operations or conditions of conventional experimental procedures described in the literature in this field. The reagents or apparatus used were conventional reagent products commercially available without the manufacturer's knowledge.
The bulk drugs in the examples below are all commercially available products.
Example 1
This example provides the traditional Chinese medicine composition of example 1-whose formulation is shown in the following table.
Table 1, chinese medicinal composition formulation
The preparation method of the traditional Chinese medicine composition of the embodiment 1 comprises the following steps:
weighing the raw materials according to the formula, adding 1 time of water, soaking for 0.5 hour, boiling the liquid medicine to 100 ℃, cooling to 60 ℃ and decocting for 0.5 hour, and filtering to obtain a first extract and medicinal residues;
adding 1 time of water into the residue, decocting the medicinal liquid to 100deg.C, decocting at 60deg.C for 0.5 hr, and filtering to obtain second extractive solution;
mixing the first extractive solution and the second extractive solution, about 300-400ml, and storing in refrigerator. The preparation method of the traditional Chinese medicine composition of the embodiment 2 comprises the following steps:
weighing the raw materials according to the formula, adding water which is 2 times of the weight of the raw materials, soaking for 0.4 hour, boiling the liquid medicine to 100 ℃, cooling to 80 ℃ and decocting for 0.4 hour, and filtering to obtain a first extract and dregs;
adding water 2 times of the weight of the medicinal residues into the medicinal residues, then decocting the medicinal liquid to 100 ℃, decocting at 80 ℃ for 0.4 hour, and filtering to obtain a second extract;
mixing the first extractive solution and the second extractive solution, about 300-400ml, and storing in refrigerator.
The preparation method of the traditional Chinese medicine composition of the embodiment 3 comprises the following steps:
weighing the raw materials according to the formula, adding water which is 2 times of the weight of the raw materials, soaking for 0.4 hour, boiling the liquid medicine to 100 ℃, cooling to 70 ℃ and decocting for 0.4 hour, and filtering to obtain a first extract and dregs;
adding 1 time of water into the residue, decocting the medicinal liquid to 100deg.C, decocting at 70deg.C for 0.4 hr, and filtering to obtain second extractive solution;
mixing the first extractive solution and the second extractive solution, about 300-400ml, and storing in refrigerator.
The preparation method of the traditional Chinese medicine composition of example 4-example 8 is the same as that of example 1.
Experimental example 1
The invention relates to a PDS model animal drug effect observation method of a traditional Chinese medicine composition
1 materials and methods
1.1 laboratory animals
SPF-class healthy male Wistar rats 110 animals, mass (200+ -20) g, supplied by Peking maintenance Tonglihua laboratory animal technologies Co., ltd. [ license number: SYXK (Beijing) 2021-0011]. The rats are adaptively bred for 6 days in a quiet and proper environment, the room temperature (22+/-2) DEG C and the relative humidity of 55-60 percent. The feeding period is enough, clean and drinking water, and the food is ingested freely.
1.2 Experimental drugs and dosages
Traditional Chinese medicine:
the Chinese medicinal compositions prepared in examples 1-8.
Positive drug:
mosapride citrate tablet (national standard H19990317): deionized water was used to prepare a drug solution having a final concentration of 1.8mg/10 ml.
1.3 major reagents and instruments
GAS rat ELISA detection kit (Shanghai enzyme-linked); 5-HT rat ELISA detection kit (Shanghai ELISA);
nutritional semi-solid preparation: 10g of sodium carboxymethylcellulose, 16g of milk powder, 8g of sugar, 8g of starch and 2g of activated carbon, adding deionized water, stirring into 300ml of black semi-solid paste, preserving in a refrigerator at 4 ℃ for standby, and taking out for standby 1h in advance.
Low temperature centrifuge, -80 ℃ refrigerator, enzyme-labeled analyzer: rayto RT-6100.
1.4 animal modeling, grouping, and administration
110 rats were randomly divided into a blank group, a model group, the groups of examples 1-8 of the Chinese medicinal composition and a positive medicine control group using EXCEL random numbers, and 10 rats each were subjected to adaptive feeding for 7 days. Except for the blank group, the remaining 100 rats were referenced to the model of the Guo moderate tail clamping method: the tail end 1/3 of the tail end of the rat tail of the model group is randomly selected and clamped by a long sponge clamp (made of gauze wrapped hemostatic forceps), the stimulation is continued for 30 minutes each time, and the rats are irritated and other rats are irritated, so that the whole-cage rats are irritated. The stimulation was performed 4 times per day (8:00-8:30, 11:30-12:00, 15:00-15:30, 18:30-19:00), 1 time at least 3h apart, for 7 days. If the fight is severe, the rat is scratched, and the injured part can be wiped by iodophor to prevent infection.
After the molding is finished, the blank group and the model group irrigate the stomach with distilled water according to the dosage of 1ml/100g, and the other groups irrigate the stomach for intervention according to the dosage of 1ml/100g of corresponding medicines. The stomach was irrigated 1 time daily for 7 consecutive days.
1.5 index detection and method
After the gastric lavage intervention is finished, all rats are fasted without water forbidding for 12 hours, 2ml of nutritional semisolid paste is given per gastric lavage, pentobarbital vein anesthesia is carried out after 30 minutes, abdominal aorta blood collection is carried out, centrifugation is carried out for 15 minutes (3000 revolutions per minute) at 4 ℃ of a low-temperature centrifuge, serum is separated, and the obtained serum is stored in a refrigerator at-20 ℃. Then dissecting and taking the complete stomach and small intestine, detecting the gastric emptying rate and the small intestine propulsion rate of the rat, and storing the data.
1.5.1 general Condition observations
General behavioral changes in the mental state, free mobility, hair status, etc. of rats before and after molding and during treatment were observed and recorded.
1.5.2 gastric emptying assay
After the gastric lavage intervention is finished, all rats are fasted without water control for 12 hours and are given 2ml of nutritional semi-solid paste per gastric lavage for 30 minutes. Then, the pentobarbital is used for intraperitoneal injection anesthesia, the gastric cardia and the pylorus of the rat are ligated after the abdominal aorta is taken, the complete stomach is cut off, the mucosa on the surface of the stomach is removed, the surface mucus and the blood are wiped by filter paper, and the weight is the weight of the whole stomach; the stomach body is cut along the greater curvature of the stomach, the stomach wall is washed clean by normal saline, the filter paper is wiped and sucked dry, and the weight is the net weight of the stomach. The gastric emptying rate was calculated using the formula.
Gastric emptying rate (%) = [1- (total stomach weight-net stomach weight)/perfused semi-solid weight ]. Times.100%.
1.5.3 determination of the small intestine Propulsion Rate
And cutting off the whole section of the small intestine (the whole section of the small intestine is from the pylorus to the upper end of the cecum), measuring the whole length of the small intestine and the distance from the pylorus to the upper edge of the carbon powder, and calculating the propulsion rate of the small intestine by using a formula.
Small intestine push rate (%) =carbon end push length/small intestine full length.
1.5.4 serum index determination
After vacuum blood collection of abdominal aorta, standing at room temperature for 2h, centrifuging at 3000r/min for 15min at 4 ℃, separating and collecting serum. The content of Gastrin (GAS) and 5-hydroxytryptamine (5-HT) in serum was determined by ELISA.
2 data statistics
Data analysis was performed using SPSS22.0 software. The measurement data of normal distribution is statistically described by adopting mean ± standard deviation, and the mean comparison between groups is performed by single factor variance analysis; the non-normal distribution of the measurement data and the technical data is statistically described by the median (quartile interval).
3 results
The results are shown in FIGS. 1-5, compared to the group of liver-stomach disharmony syndrome PDS models. As can be seen from fig. 1, the examples 1-8 and the positive drug groups significantly improved the gastric emptying rate compared to the model group. As can be seen from fig. 2 and 3, the example 1-example 8 and the positive drug group significantly improved the small intestine propulsion rate compared to the model group. As can be seen from fig. 4, the example 1-example 8 and the positive drug group significantly increased the content of GAS in serum compared to the model group. As can be seen from fig. 5, the example 1-example 8 and positive drug groups significantly increased the 5-HT content in serum compared to the model group.
In conclusion, the traditional Chinese medicine composition can effectively improve the gastric emptying rate and the small intestine propulsion rate of a PDS rat with incoordination between liver and stomach, obviously lighten the postprandial discomfort syndrome, and simultaneously effectively lighten the anxiety state of a model rat by improving the protein expression quantity of gastrointestinal hormones such as GAS, 5-HT and the like and ghrelin in serum.
It is apparent that the above examples are given by way of illustration only and are not limiting of the embodiments. Other variations or modifications of the above teachings will be apparent to those of ordinary skill in the art. It is not necessary here nor is it exhaustive of all embodiments. While still being apparent from variations or modifications that may be made by those skilled in the art are within the scope of the invention.
Claims (9)
1. The traditional Chinese medicine composition is characterized by comprising the following raw materials in parts by weight: 3-20 parts of radix bupleuri, 3-20 parts of radix scutellariae, 3-18 parts of ginger processed pinellia, 3-30 parts of lucid ganoderma, 3-30 parts of cassia twig, 3-30 parts of raw white paeony root, 3-15 parts of magnolia officinalis, 2-15 parts of sandalwood, 0.1-3 parts of pearl powder, 1-10 parts of hypericum perforatum, 3-18 parts of cape jasmine and 3-24 parts of snakegourd fruit.
2. The traditional Chinese medicine composition according to claim 1, which is characterized by comprising the following raw materials in parts by weight:
3-18 parts of radix bupleuri, 3-15 parts of radix scutellariae, 3-15 parts of ginger processed pinellia, 3-20 parts of lucid ganoderma, 3-20 parts of cassia twig, 3-20 parts of raw white paeony root, 3-12 parts of magnolia officinalis, 2-10 parts of sandalwood, 0.1-1.5 parts of pearl powder, 1-9 parts of hypericum perforatum, 3-15 parts of gardenia and 3-18 parts of snakegourd fruit.
3. The traditional Chinese medicine composition according to claim 1 or 2, which is characterized by comprising the following raw materials in parts by weight:
5-15 parts of radix bupleuri, 3-12 parts of radix scutellariae, 3-12 parts of ginger processed pinellia, 3-12 parts of lucid ganoderma, 3-12 parts of cassia twig, 3-15 parts of raw white paeony root, 3-10 parts of magnolia officinalis, 2-8 parts of sandalwood, 0.1-1 part of pearl powder, 1-6 parts of hypericum perforatum, 3-12 parts of gardenia and 3-12 parts of snakegourd fruit.
4. The traditional Chinese medicine composition according to any one of claims 1 to 3, which is characterized by comprising the following raw materials in parts by weight:
5-10 parts of radix bupleuri, 3-9 parts of radix scutellariae, 3-9 parts of ginger processed pinellia, 3-9 parts of lucid ganoderma, 3-9 parts of cassia twig, 9-15 parts of raw white paeony root, 6-10 parts of magnolia officinalis, 2-5 parts of sandalwood, 0.3-1 part of pearl powder, 1-3 parts of hypericum perforatum, 3-9 parts of cape jasmine and 3-9 parts of snakegourd fruit.
5. A method of preparing a Chinese medicinal composition according to any one of claims 1 to 4, comprising:
the preparation method comprises the steps of weighing raw materials according to a formula, and extracting with water.
6. The method for preparing a Chinese medicinal composition according to claim 5, comprising the steps of:
weighing the raw materials according to the formula, adding 1-2 times of water, soaking for 0.4-0.5 hr, decocting the medicinal liquid to 100deg.C, cooling to 60-80deg.C, decocting for 0.4-0.5 hr, and filtering to obtain first extractive solution and residue;
adding water 1-2 times of the weight of the medicinal residues into the medicinal residues, decocting the medicinal liquid to 100deg.C, cooling to 60-80deg.C, decocting for 0.4-0.5 hr, and filtering to obtain second extractive solution;
mixing the first extractive solution and the second extractive solution.
7. A Chinese medicinal preparation, which is characterized by comprising the Chinese medicinal composition prepared by the preparation method of the Chinese medicinal composition according to any one of claims 1-4 or the Chinese medicinal composition according to claim 5 or 6 as an active ingredient.
8. The traditional Chinese medicine preparation according to claim 7, further comprising pharmaceutically acceptable excipients;
optionally, the form of the traditional Chinese medicine preparation comprises a liquid preparation or a solid preparation;
optionally, the dosage form of the traditional Chinese medicine preparation comprises injection, tablet, capsule, powder, granule or paste.
9. The traditional Chinese medicine composition according to any one of claims 1 to 4, the traditional Chinese medicine composition prepared by the preparation method of the traditional Chinese medicine composition according to claim 5 or 6 or the traditional Chinese medicine preparation according to claim 7 or 8 has the following purposes:
(1) Use in the manufacture of a medicament for the alleviation, adjuvant treatment or treatment of functional dyspepsia;
(2) The application of the composition in preparing medicines for relieving, assisting in treating or treating anxiety and depression;
(3) The use in the manufacture of a medicament for the relief, adjuvant treatment or treatment of functional dyspepsia with anxiety depression;
(4) Use in the manufacture of a medicament for increasing the protein expression levels of gastrointestinal hormones and ghrelins in serum;
optionally, the functional dyspepsia is postprandial malaise syndrome.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310156735.2A CN116159102B (en) | 2023-02-09 | 2023-02-09 | Traditional Chinese medicine composition for treating postprandial discomfort syndrome as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310156735.2A CN116159102B (en) | 2023-02-09 | 2023-02-09 | Traditional Chinese medicine composition for treating postprandial discomfort syndrome as well as preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116159102A true CN116159102A (en) | 2023-05-26 |
| CN116159102B CN116159102B (en) | 2023-12-26 |
Family
ID=86421660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310156735.2A Active CN116159102B (en) | 2023-02-09 | 2023-02-09 | Traditional Chinese medicine composition for treating postprandial discomfort syndrome as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116159102B (en) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105477622A (en) * | 2016-01-24 | 2016-04-13 | 青岛云天生物技术有限公司 | Medicinal preparation for treating functional dyspepsia and application of medicinal preparation |
| CN105497750A (en) * | 2015-12-28 | 2016-04-20 | 天长市中医院 | Radix bupleuri and radix scutellariae stomach-soothing traditional Chinese medicine composition and application thereof |
| CN106109895A (en) * | 2016-07-12 | 2016-11-16 | 杨高林 | A kind of Chinese medicine composition treating phlegm stagnation fire type chronic pharyngitis and method |
| CN107812159A (en) * | 2017-12-02 | 2018-03-20 | 代立新 | A kind of Chinese medicine composition for treating functional dyspepsia FD and preparation method thereof |
| CN108686070A (en) * | 2018-07-16 | 2018-10-23 | 资兴市泰坤农林生态产业有限公司 | A kind of livestock stomach strengthening and digestion promoting composition and preparation method thereof |
| CN109045201A (en) * | 2018-10-26 | 2018-12-21 | 上海市中医医院 | For treating chronic digestible tract disease with the Chinese medicine composition of anxiety-depression state |
| CN110833609A (en) * | 2018-08-16 | 2020-02-25 | 中国中医科学院望京医院 | Traditional Chinese medicine composition for treating dyspepsia |
| CN111643588A (en) * | 2020-07-24 | 2020-09-11 | 鱼涛 | Traditional Chinese medicine composition for treating functional dyspepsia and preparation method of capsule thereof |
| CN112675281A (en) * | 2021-01-19 | 2021-04-20 | 韩军营 | Foot bath soup for treating depression and insomnia |
| CN115429864A (en) * | 2019-11-29 | 2022-12-06 | 王宇红 | Traditional Chinese medicine composition for treating depression |
-
2023
- 2023-02-09 CN CN202310156735.2A patent/CN116159102B/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105497750A (en) * | 2015-12-28 | 2016-04-20 | 天长市中医院 | Radix bupleuri and radix scutellariae stomach-soothing traditional Chinese medicine composition and application thereof |
| CN105477622A (en) * | 2016-01-24 | 2016-04-13 | 青岛云天生物技术有限公司 | Medicinal preparation for treating functional dyspepsia and application of medicinal preparation |
| CN106109895A (en) * | 2016-07-12 | 2016-11-16 | 杨高林 | A kind of Chinese medicine composition treating phlegm stagnation fire type chronic pharyngitis and method |
| CN107812159A (en) * | 2017-12-02 | 2018-03-20 | 代立新 | A kind of Chinese medicine composition for treating functional dyspepsia FD and preparation method thereof |
| CN108686070A (en) * | 2018-07-16 | 2018-10-23 | 资兴市泰坤农林生态产业有限公司 | A kind of livestock stomach strengthening and digestion promoting composition and preparation method thereof |
| CN110833609A (en) * | 2018-08-16 | 2020-02-25 | 中国中医科学院望京医院 | Traditional Chinese medicine composition for treating dyspepsia |
| CN109045201A (en) * | 2018-10-26 | 2018-12-21 | 上海市中医医院 | For treating chronic digestible tract disease with the Chinese medicine composition of anxiety-depression state |
| CN115429864A (en) * | 2019-11-29 | 2022-12-06 | 王宇红 | Traditional Chinese medicine composition for treating depression |
| CN111643588A (en) * | 2020-07-24 | 2020-09-11 | 鱼涛 | Traditional Chinese medicine composition for treating functional dyspepsia and preparation method of capsule thereof |
| CN112675281A (en) * | 2021-01-19 | 2021-04-20 | 韩军营 | Foot bath soup for treating depression and insomnia |
Non-Patent Citations (6)
| Title |
|---|
| 刘会红;李莲英;: "柴胡疏肝散合瓜蒌半夏汤加减方联合黛力新治疗冠心病合并抑郁焦虑疗效观察", 现代中西医结合杂志, no. 24, pages 65 - 68 * |
| 张雷永;朱迪;: "中医药治疗功能性消化不良概况", 湖南中医杂志, no. 02, pages 144 - 146 * |
| 李影华;: "四逆散加味治疗肝胃不和型功能性消化不良50例", 山东中医杂志, no. 11, pages 29 - 30 * |
| 王会丽;高天曙;杨小平;赵玉瑶;: "柴胡桂枝干姜汤联合氟哌噻吨美利曲辛治疗顽固性功能性消化不良60例", 中医研究, no. 10, pages 31 - 33 * |
| 王毅;: "辨证分型治疗功能性消化不良86例", 四川中医, no. 06, pages 53 - 54 * |
| 范肖芳;: "中西医结合治疗功能性消化不良75例", 新中医, no. 07, pages 72 - 73 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116159102B (en) | 2023-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102205107B (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN111544550B (en) | Traditional Chinese medicine formula flora capsule, preparation method and application in preparation of medicine for treating type 2 diabetes | |
| CN108277138A (en) | A kind of health-care and nutritious wine and preparation method thereof | |
| CN104324291A (en) | Traditional Chinese medicine preparation for treating large intestine damp-heat type hemafecia and preparation method of traditional Chinese medicine preparation | |
| CN101695527B (en) | Toxin-expelling intestine-moistening Chinese medicinal preparation and preparation method thereof | |
| CN106540181A (en) | A kind of Chinese medicine for treating diabetes | |
| CN116159102B (en) | Traditional Chinese medicine composition for treating postprandial discomfort syndrome as well as preparation method and application thereof | |
| CN106334171B (en) | A kind of Chinese medicine preparation and preparation method for being used to repair hepatic injury | |
| CN104623314A (en) | Medicine composition for treating dry mouth and bitter taste and preparation method thereof | |
| CN104490904B (en) | It is a kind of to treat neurasthenic pharmaceutical composition and preparation method thereof | |
| CN103393938B (en) | Traditional Chinese medicine composition for reducing blood sugar | |
| CN102988747B (en) | Aristida triseta electuary for reducing hypertension, hyperglycemia and hyperlipidemia and preparation method thereof | |
| CN102274428B (en) | Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof | |
| CN109718304A (en) | Improve the Chinese medicine composition of the microcirculation of human body cardio and vascular function and pre- preventing thrombosis | |
| CN106729206B (en) | Traditional Chinese medicine composition with effects of tonifying spleen, eliminating dampness, promoting qi circulation and inducing diuresis, dampness eliminating granules and preparation method thereof | |
| CN116549520A (en) | Qi-blood tonifying, lung heat clearing and cough relieving traditional Chinese medicine formula, traditional Chinese medicine liquid and traditional Chinese medicine preparation | |
| CN101708230A (en) | Narcotic-abstaining medicine and preparation method thereof | |
| CN1895503A (en) | Hairy antler capsules | |
| CN105497459A (en) | Traditional Chinese medicine preparation for treating woman leukorrheal diseases as well as preparation method and application of traditional Chinese medicine preparation | |
| CN105106884B (en) | Qi and activate blood circulation lets out turbid side | |
| CN116211953A (en) | Traditional Chinese medicine composition for treating upper abdominal pain syndrome, preparation method and application | |
| CN105106817A (en) | Yao medicine compound broadleaf globethistle inflorescence tablet for treating diabetes and preparation method thereof | |
| CN104800646A (en) | Traditional Chinese medicine combination for treating burning month syndrome and preparation method thereof | |
| CN104173808B (en) | A kind of Chinese medicine and preparation method thereof for treating flaming-up of the liverfire type hypertension | |
| CN104474421A (en) | Traditional Chinese medicine preparation for treating night terror crying of children and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |